Media headlines about Wave Life Sciences (NASDAQ:WVE) have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Wave Life Sciences earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.6263711781956 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Wave Life Sciences (WVE) PT Set at $49.00 by HC Wainwright (americanbankingnews.com)
- Wave Life Sciences (WVE) Releases Earnings Results (americanbankingnews.com)
- Mizuho Analysts Give Wave Life Sciences (WVE) a $65.00 Price Target (americanbankingnews.com)
- Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates (finance.yahoo.com)
- Wave Life Sciences up 5% premarket on Q2 results (seekingalpha.com)
Wave Life Sciences stock opened at $44.00 on Friday. Wave Life Sciences has a 12 month low of $16.05 and a 12 month high of $55.95. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.43 and a beta of 0.69.
WVE has been the subject of several research reports. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, May 30th. HC Wainwright set a $49.00 target price on Wave Life Sciences and gave the company a “buy” rating in a research report on Friday. Mizuho set a $65.00 target price on Wave Life Sciences and gave the company a “buy” rating in a research report on Thursday. Stifel Nicolaus initiated coverage on Wave Life Sciences in a research report on Monday, August 6th. They issued a “buy” rating and a $56.00 target price for the company. Finally, ValuEngine upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $58.40.
In other news, insider Paul Bolno sold 31,711 shares of the firm’s stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $45.00, for a total transaction of $1,426,995.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chris Francis sold 48,992 shares of the firm’s stock in a transaction dated Friday, June 1st. The stock was sold at an average price of $46.75, for a total value of $2,290,376.00. The disclosure for this sale can be found here. Insiders have sold 105,199 shares of company stock valued at $4,630,337 over the last 90 days. 44.20% of the stock is owned by corporate insiders.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Recommended Story: What does earnings per share mean?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.